Multi-Centric Observational Study to Analyze the Diagnostic Molecular Features in the Clinical Setting of Lung Allograft Biopsies
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 700
- 试验地点
- 20
- 主要终点
- Report the molecular scores (probability) of lung transplant disease in a reference set of 600 transbronchial biopsies.
研究概览
简要总结
Objective: To evaluate the potential impact of molecular phenotyping of transbronchial biopsies in lung transplant recipients with allograft dysfunction, and the potential for developing a safer endobronchial mucosal biopsy format.
详细描述
The current standard for biopsy-based diagnoses of dysfunction of lung transplants is the International Society of Heart and Lung Transplantation (ISHLT) classification applied to transbronchial biopsies, which represents an arbitrary international consensus. Recent data-driven approaches using molecular and conventional technologies indicate that this system produces frequently incorrect diagnoses with potential harm to patients due to inappropriate treatment. especially in relationship to the correct diagnosis of chronic lung allograft dysfunction is a pressing need. To address this unmet need and improve diagnostics in the area of organ transplantation, the Alberta Transplant Applied Genomics Centre (ATAGC, University of Alberta) has developed a new diagnostic system - the Molecular Microscope® Diagnostic System (MMDx) that interprets biopsies in terms of their molecular phenotype. The MMDx, developed first in kidney transplant biopsies with thoroughly established phenotypes, will now be adapted to lung transplant transbronchial biopsies (TBBs). Microarray analysis of lung allograft biopsy specimens will be compared to conventional allograft phenotyping, including clinical, physiologic, radiographic and histological assessment. The present study will use the MMDx™ system to assess and report TBBs, and validate and refine this system in 300 unselected prospectively collected lung TBBs. A subset of the study will examine the third bifurcation mucosal endobronchial biopsies (3BMBs) paired with TBBs from 50 patients to see if the safer 3BMBs can substitute for the TBB to be used by MMDx™. Due to a considerable interest and support from participating Centers, the study is further extended and collected 1032 TBBs and 602 3BMBs from 849 patients. This this is the extension of the INTERLUNG study - INTERLUNGEX.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All lung transplant recipients undergoing a biopsy as determined by their surgeon or physician.
排除标准
- •Patients who declined participation or unable to give informed consent.
结局指标
主要结局
Report the molecular scores (probability) of lung transplant disease in a reference set of 600 transbronchial biopsies.
时间窗: two years
Molecular classifier predicts antibody mediated and T cell mediated rejection, and chronic allograft dysfunction.
Report the molecular diagnoses of the MMDx-TBB system
时间窗: two years
Compare MMDx readings to standard-of-care TBB histology and clinical diagnosis of CLAD.
次要结局
- Report the molecular diagnoses of the MMDx-3BMB system(two years)
- Report the molecular scores (probability) of lung transplant disease in a reference set of 600 mucosal endobronchial biopsies.(two years)
- Report the molecular changes over time in medically indicated follow-up biopsies(two years)
研究者
Philip Halloran
Distinguished Professor
University of Alberta
